SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Phaarmasia - Quaterly Results

13 Feb 2023 Evaluate
The total revenue surged to Rs. 79.42 millions, up 105.06% for the December 2022 quarter as against Rs. 38.73 millions during the year-ago period.The Net Loss for the quarter ended December 2022 is Rs. -5.92 millions as compared to Net Loss of Rs. -7.28 millions of corresponding quarter ended December 2021 Operating profit Margin for the quarter ended December 2022 improved to -5.26% as compared to -6.65% of corresponding quarter ended December 2021


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202212 202112 % Var 202212 202112 % Var 202203 202103 % Var
Sales 79.42 38.73 105.06 199.86 130.53 53.11 172.16 198.95 -13.47
Other Income 1.14 0.81 40.74 3.75 3.15 19.05 4.70 8.94 -47.43
PBIDT -5.26 -6.65 -20.90 -9.57 -11.85 -19.24 -12.65 8.32 -252.04
Interest 0.05 0.01 400.00 0.13 0.03 333.33 0.04 0.12 -66.67
PBDT -5.31 -6.66 -20.27 -9.70 -11.88 -18.35 -12.69 8.20 -254.76
Depreciation 0.64 0.74 -13.51 1.91 2.21 -13.57 2.92 3.42 -14.62
PBT -5.95 -7.40 -19.59 -11.61 -14.09 -17.60 -15.61 4.78 -426.57
TAX -0.03 -0.12 -75.00 0.05 -0.12 -141.67 -0.15 1.67 -108.98
Deferred Tax -0.03 -0.12 -75.00 0.05 -0.12 -141.67 -0.15 -0.18 -16.67
PAT -5.92 -7.28 -18.68 -11.66 -13.97 -16.54 -15.46 3.11 -597.11
Equity 68.27 68.27 0.00 68.27 68.27 0.00 68.27 68.27 0.00
PBIDTM(%) -6.62 -17.17 -61.43 -4.79 -9.08 -47.26 -7.35 4.18 -275.70

Phaarmasia Share Price

113.80 1.80 (1.61%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×